levomilnacipran hydrochloride · Abbvie · NDA 204168
Fetzima
Earliest generic entry, as listed · earliest of 4 marketed strengths
23 May 2032
Blocked by patent: US 8865937.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8865937 | substance, product | 23 May 2032 |
| US 8481598 | use U-839 | 2 Mar 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 204168 · 001 · RLD | capsule, extended release, oral | EQ 20MG BASE | 23 May 2032 |
| 204168 · 002 · RLD | capsule, extended release, oral | EQ 40MG BASE | 23 May 2032 |
| 204168 · 003 · RLD | capsule, extended release, oral | EQ 80MG BASE | 23 May 2032 |
| 204168 · 004 · RLD | capsule, extended release, oral | EQ 120MG BASE | 23 May 2032 |
Expired or delisted (2)
- US RE43879 · use U-839 · 11 Jan 2026
- M-304 · 24 Mar 2026